Renaissance Group LLC acquired a new stake in shares of Danaher Co. (NYSE:DHR – Get Rating) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 94,139 shares of the conglomerate’s stock, valued at approximately $30,973,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. purchased a new position in Danaher during the fourth quarter worth about $28,000. Dixon Hughes Goodman Wealth Advisors LLC purchased a new position in Danaher in the fourth quarter valued at about $29,000. Lee Financial Co purchased a new position in Danaher in the fourth quarter valued at about $30,000. Evolution Advisers Inc. purchased a new position in Danaher in the fourth quarter valued at about $32,000. Finally, Dark Forest Capital Management LP bought a new stake in shares of Danaher in the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 78.42% of the company’s stock.
Shares of NYSE:DHR traded up $2.49 during midday trading on Friday, reaching $251.80. 2,419,961 shares of the company’s stock traded hands, compared to its average volume of 2,984,268. The company has a fifty day simple moving average of $270.95 and a two-hundred day simple moving average of $287.43. Danaher Co. has a 1 year low of $233.71 and a 1 year high of $333.96. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.27 and a current ratio of 1.68. The company has a market cap of $183.08 billion, a P/E ratio of 29.14, a PEG ratio of 2.71 and a beta of 0.84.
The business also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Friday, June 24th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Thursday, June 23rd. Danaher’s dividend payout ratio (DPR) is presently 11.57%.
A number of research firms recently weighed in on DHR. Zacks Investment Research lowered shares of Danaher from a “buy” rating to a “hold” rating and set a $278.00 target price on the stock. in a report on Monday, April 25th. Wells Fargo & Company cut shares of Danaher from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $330.00 to $265.00 in a research note on Monday, April 25th. UBS Group dropped their price target on shares of Danaher from $365.00 to $340.00 in a research report on Sunday, April 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Finally, Robert W. Baird decreased their price target on shares of Danaher from $334.00 to $319.00 and set an “outperform” rating for the company in a research note on Friday, April 22nd. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of “Buy” and a consensus target price of $331.14.
In other Danaher news, EVP Joakim Weidemanis sold 6,500 shares of the firm’s stock in a transaction on Monday, April 25th. The stock was sold at an average price of $255.74, for a total value of $1,662,310.00. Following the completion of the sale, the executive vice president now directly owns 86,398 shares of the company’s stock, valued at approximately $22,095,424.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.20% of the stock is owned by company insiders.
Danaher Company Profile (Get Rating)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.
- Get a free copy of the StockNews.com research report on Danaher (DHR)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.